STOK.OQ - Stoke Therapeutics Inc
Canaccord GenuityEstimate Increase, Recommendation Increase, Price Target Increase
Taking a harder look at zorenuversen's value proposition in Dravet syndrome drives our PT up from $36 to $60; reiterate BUY
公司
STOK.OQ
日期
2026-03-19
分析师
Sumant Kulkarni
页数
15 页
需要登录
请登录后购买研报或生成音频内容。